Ananda Pharma（ANAN.F）株式概要Ananda Pharma Plcは、その子会社とともに、英国内外の薬用・治療用大麻市場に投資している。 詳細ANAN.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6リスク分析過去5年間で収益は年間47.5%減少しました。 収益が 100 万ドル未満 ( £4K )株式の流動性は非常に低い 意味のある時価総額がありません ( $5M )すべてのリスクチェックを見るANAN.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW483,745 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA483,745 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.0011746.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-14m134k2016201920222025202620282031Revenue UK£134.2kEarnings UK£19.4kAdvancedSet Fair ValueView all narrativesAnanda Pharma Plc 競合他社PRF TechnologiesSymbol: NasdaqCM:PRFXMarket cap: US$3.0mCitius PharmaceuticalsSymbol: NasdaqCM:CTXRMarket cap: US$15.4mCocrystal PharmaSymbol: NasdaqCM:COCPMarket cap: US$21.0mHyperion DeFiSymbol: NasdaqCM:HYPDMarket cap: US$44.1m価格と性能株価の高値、安値、推移の概要Ananda Pharma過去の株価現在の株価US$0.001152週高値US$0.006252週安値US$0.0011ベータ0.651ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-82.26%最新ニュースお知らせ • Jul 19Ananda Pharma Limited Doses First Patient In ACTiON Clinical Trial For MRX1 In Chemotherapy Induced Peripheral NeuropathyAnanda Pharma Limited has dosed the first patient in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's proprietary CBD-based drug candidate, in treatment of patients with Chemotherapy Induced Peripheral Neuropathy. The patient has been recruited, randomised and has taken their first dose of either MRX1 or placebo on the trial. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research as a non-dilutive Efficacy and Mechanism Evaluation grant, is designed to assess the efficacy and safety of MRX1 in the treatment of Chemotherapy Induced Peripheral Neuropathy. It will also assess the impact of MRX1 on quality of life and healthcare utilisation. The trial is a double-blind, placebo-controlled, crossover study with a target enrolment of 92 participants. Chemotherapy Induced Peripheral Neuropathy is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of Chemotherapy Induced Peripheral Neuropathy per year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTiON (Chemotherapy Induced Peripheral Neuropathy, funded by an NIHR Efficacy and Mechanism Evaluation grant).お知らせ • Jul 06Ananda Pharma Delivers MRX1 Investigational Product To University Of Edinburgh Central Pharmacy For ACTiON Phase 2 Clinical TrialAnanda Pharma announced the MRX1 investigational product manufactured in 2025 has been delivered to the University of Edinburgh central pharmacy. This shipment supports the initiation of the ACTiON Phase 2 clinical trial, which is being run in partnership with the University of Edinburgh. Participant screening is now underway at the clinical trial site in preparation for first participant first dose. This milestone marks a significant step on the clinical development pathway as it brings Ananda closer to dosing its first ever Phase 2 clinical trial patient with MRX1, following the successful completion of its first in-human study earlier this year. The Company will provide further updates when first participant first dose has been confirmed. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR) as an Efficacy and Mechanism Evaluation (EME) grant, is designed to assess the efficacy and safety of MRX1 in the treatment of CIPN. It will also assess the impact of MRX1 on quality of life and health care utilisation. The trial is a double-blind, placebo controlled, crossover study with a target enrolment of 92 participants. CIPN is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of CIPN/year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University of Edinburgh.お知らせ • Jun 19+ 1 more updateAnanda Pharma Limited Completes Phase 1 MRX1 Pharmacokinetic Study and Confirms Favourable Safety and TolerabilityAnanda Pharma Limited has completed its Phase 1 pharmacokinetic study, yielding highly encouraging data that confirms favourable safety and tolerability and dose selection for future clinical studies. The positive outcomes of the study support continued clinical investigation into Phase 2 and provide further confidence in the Company's clinical and regulatory strategy. MRX1 demonstrated a favourable tolerability profile under the conditions evaluated in healthy volunteers following twice daily dosing for 6 days at dosing levels of 2.5 mg/kg and 7.5 mg/kg per dose under fasted conditions and following a single dose at 2.5 mg/kg under fed conditions. All reported Treatment Emergent Adverse Events ('TEAEs') were mild in severity. There were no moderate or severe TEAEs or TEAEs that led to study drug discontinuation, study withdrawal or death. There were no meaningful changes over time observed for any clinical laboratory parameter, and no abnormal clinically significant laboratory parameters were reported at any time during the study, including liver function parameters. This safety and tolerability profile was consistent with the established clinical profile of approved CBD therapies, a finding that supports the scientific rationale underpinning our FDA 505(b)(2) development pathway. The Phase 1 study was designed to assess the pharmacokinetics, safety and tolerability of multiple doses of MRX1 in healthy adult volunteers. Two dose levels were tested, 2.5 and 7.5 mg/kg of body weight. The effect of food was also assessed for lower dose level (2.5 mg/kg). A total of 20 participants received at least one dose of MRX1, with 10 participants 2.5 mg/kg twice daily and 10 receiving 7.5 mg/kg twice daily. After a 14-day wash-out period, 9 of the 10 participants who had previously been dosed with MRX1 2.5 mg/kg in Period 1 received a single dose of MRX1 2.5 mg/kg after consuming a high-fat, high-calorie meal.お知らせ • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.お知らせ • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".お知らせ • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom最新情報をもっと見るRecent updatesお知らせ • Jul 19Ananda Pharma Limited Doses First Patient In ACTiON Clinical Trial For MRX1 In Chemotherapy Induced Peripheral NeuropathyAnanda Pharma Limited has dosed the first patient in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's proprietary CBD-based drug candidate, in treatment of patients with Chemotherapy Induced Peripheral Neuropathy. The patient has been recruited, randomised and has taken their first dose of either MRX1 or placebo on the trial. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research as a non-dilutive Efficacy and Mechanism Evaluation grant, is designed to assess the efficacy and safety of MRX1 in the treatment of Chemotherapy Induced Peripheral Neuropathy. It will also assess the impact of MRX1 on quality of life and healthcare utilisation. The trial is a double-blind, placebo-controlled, crossover study with a target enrolment of 92 participants. Chemotherapy Induced Peripheral Neuropathy is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of Chemotherapy Induced Peripheral Neuropathy per year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTiON (Chemotherapy Induced Peripheral Neuropathy, funded by an NIHR Efficacy and Mechanism Evaluation grant).お知らせ • Jul 06Ananda Pharma Delivers MRX1 Investigational Product To University Of Edinburgh Central Pharmacy For ACTiON Phase 2 Clinical TrialAnanda Pharma announced the MRX1 investigational product manufactured in 2025 has been delivered to the University of Edinburgh central pharmacy. This shipment supports the initiation of the ACTiON Phase 2 clinical trial, which is being run in partnership with the University of Edinburgh. Participant screening is now underway at the clinical trial site in preparation for first participant first dose. This milestone marks a significant step on the clinical development pathway as it brings Ananda closer to dosing its first ever Phase 2 clinical trial patient with MRX1, following the successful completion of its first in-human study earlier this year. The Company will provide further updates when first participant first dose has been confirmed. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR) as an Efficacy and Mechanism Evaluation (EME) grant, is designed to assess the efficacy and safety of MRX1 in the treatment of CIPN. It will also assess the impact of MRX1 on quality of life and health care utilisation. The trial is a double-blind, placebo controlled, crossover study with a target enrolment of 92 participants. CIPN is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of CIPN/year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University of Edinburgh.お知らせ • Jun 19+ 1 more updateAnanda Pharma Limited Completes Phase 1 MRX1 Pharmacokinetic Study and Confirms Favourable Safety and TolerabilityAnanda Pharma Limited has completed its Phase 1 pharmacokinetic study, yielding highly encouraging data that confirms favourable safety and tolerability and dose selection for future clinical studies. The positive outcomes of the study support continued clinical investigation into Phase 2 and provide further confidence in the Company's clinical and regulatory strategy. MRX1 demonstrated a favourable tolerability profile under the conditions evaluated in healthy volunteers following twice daily dosing for 6 days at dosing levels of 2.5 mg/kg and 7.5 mg/kg per dose under fasted conditions and following a single dose at 2.5 mg/kg under fed conditions. All reported Treatment Emergent Adverse Events ('TEAEs') were mild in severity. There were no moderate or severe TEAEs or TEAEs that led to study drug discontinuation, study withdrawal or death. There were no meaningful changes over time observed for any clinical laboratory parameter, and no abnormal clinically significant laboratory parameters were reported at any time during the study, including liver function parameters. This safety and tolerability profile was consistent with the established clinical profile of approved CBD therapies, a finding that supports the scientific rationale underpinning our FDA 505(b)(2) development pathway. The Phase 1 study was designed to assess the pharmacokinetics, safety and tolerability of multiple doses of MRX1 in healthy adult volunteers. Two dose levels were tested, 2.5 and 7.5 mg/kg of body weight. The effect of food was also assessed for lower dose level (2.5 mg/kg). A total of 20 participants received at least one dose of MRX1, with 10 participants 2.5 mg/kg twice daily and 10 receiving 7.5 mg/kg twice daily. After a 14-day wash-out period, 9 of the 10 participants who had previously been dosed with MRX1 2.5 mg/kg in Period 1 received a single dose of MRX1 2.5 mg/kg after consuming a high-fat, high-calorie meal.お知らせ • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.お知らせ • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".お知らせ • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom株主還元ANAN.FUS PharmaceuticalsUS 市場7D0%2.3%-0.3%1Yn/a53.6%19.9%株主還元を見る業界別リターン: ANAN.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: ANAN.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is ANAN.F's price volatile compared to industry and market?ANAN.F volatilityANAN.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.0%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.1%安定した株価: ANAN.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のANAN.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20189Melissa Sturgessanandadevelopments.comAnanda Pharma Plcは、その子会社とともに、英国および国際的な薬用・治療用大麻市場に投資している。同社は、慢性炎症性疼痛疾患の治療薬として、カンナビノイドベースの医薬品を提供している。また、メロンや根塊茎の栽培、健康食品の開発・販売、医薬品の卸売、オーガニックベーシックオイルやエッセンシャルオイルの製造・販売、農作物の生産活動も行っている。同社は以前はAnanda Developments Plcとして知られ、2024年12月にAnanda Pharma Plcに社名を変更した。Ananda Pharma Plcは2018年に法人化され、英国ロンドンに拠点を置く。もっと見るAnanda Pharma Plc 基礎のまとめAnanda Pharma の収益と売上を時価総額と比較するとどうか。ANAN.F 基礎統計学時価総額US$4.89m収益（TTM）-US$6.09m売上高(TTM)US$5.98k818.4xP/Sレシオ-0.8xPER（株価収益率ANAN.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ANAN.F 損益計算書（TTM）収益UK£4.43k売上原価UK£0売上総利益UK£4.43kその他の費用UK£4.52m収益-UK£4.51m直近の収益報告Jul 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.001グロス・マージン100.00%純利益率-101,771.51%有利子負債／自己資本比率268.7%ANAN.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/23 19:35終値2025/11/26 00:00収益2025/07/31年間収益2025/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ananda Pharma Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 19Ananda Pharma Limited Doses First Patient In ACTiON Clinical Trial For MRX1 In Chemotherapy Induced Peripheral NeuropathyAnanda Pharma Limited has dosed the first patient in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's proprietary CBD-based drug candidate, in treatment of patients with Chemotherapy Induced Peripheral Neuropathy. The patient has been recruited, randomised and has taken their first dose of either MRX1 or placebo on the trial. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research as a non-dilutive Efficacy and Mechanism Evaluation grant, is designed to assess the efficacy and safety of MRX1 in the treatment of Chemotherapy Induced Peripheral Neuropathy. It will also assess the impact of MRX1 on quality of life and healthcare utilisation. The trial is a double-blind, placebo-controlled, crossover study with a target enrolment of 92 participants. Chemotherapy Induced Peripheral Neuropathy is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of Chemotherapy Induced Peripheral Neuropathy per year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTiON (Chemotherapy Induced Peripheral Neuropathy, funded by an NIHR Efficacy and Mechanism Evaluation grant).
お知らせ • Jul 06Ananda Pharma Delivers MRX1 Investigational Product To University Of Edinburgh Central Pharmacy For ACTiON Phase 2 Clinical TrialAnanda Pharma announced the MRX1 investigational product manufactured in 2025 has been delivered to the University of Edinburgh central pharmacy. This shipment supports the initiation of the ACTiON Phase 2 clinical trial, which is being run in partnership with the University of Edinburgh. Participant screening is now underway at the clinical trial site in preparation for first participant first dose. This milestone marks a significant step on the clinical development pathway as it brings Ananda closer to dosing its first ever Phase 2 clinical trial patient with MRX1, following the successful completion of its first in-human study earlier this year. The Company will provide further updates when first participant first dose has been confirmed. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR) as an Efficacy and Mechanism Evaluation (EME) grant, is designed to assess the efficacy and safety of MRX1 in the treatment of CIPN. It will also assess the impact of MRX1 on quality of life and health care utilisation. The trial is a double-blind, placebo controlled, crossover study with a target enrolment of 92 participants. CIPN is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of CIPN/year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University of Edinburgh.
お知らせ • Jun 19+ 1 more updateAnanda Pharma Limited Completes Phase 1 MRX1 Pharmacokinetic Study and Confirms Favourable Safety and TolerabilityAnanda Pharma Limited has completed its Phase 1 pharmacokinetic study, yielding highly encouraging data that confirms favourable safety and tolerability and dose selection for future clinical studies. The positive outcomes of the study support continued clinical investigation into Phase 2 and provide further confidence in the Company's clinical and regulatory strategy. MRX1 demonstrated a favourable tolerability profile under the conditions evaluated in healthy volunteers following twice daily dosing for 6 days at dosing levels of 2.5 mg/kg and 7.5 mg/kg per dose under fasted conditions and following a single dose at 2.5 mg/kg under fed conditions. All reported Treatment Emergent Adverse Events ('TEAEs') were mild in severity. There were no moderate or severe TEAEs or TEAEs that led to study drug discontinuation, study withdrawal or death. There were no meaningful changes over time observed for any clinical laboratory parameter, and no abnormal clinically significant laboratory parameters were reported at any time during the study, including liver function parameters. This safety and tolerability profile was consistent with the established clinical profile of approved CBD therapies, a finding that supports the scientific rationale underpinning our FDA 505(b)(2) development pathway. The Phase 1 study was designed to assess the pharmacokinetics, safety and tolerability of multiple doses of MRX1 in healthy adult volunteers. Two dose levels were tested, 2.5 and 7.5 mg/kg of body weight. The effect of food was also assessed for lower dose level (2.5 mg/kg). A total of 20 participants received at least one dose of MRX1, with 10 participants 2.5 mg/kg twice daily and 10 receiving 7.5 mg/kg twice daily. After a 14-day wash-out period, 9 of the 10 participants who had previously been dosed with MRX1 2.5 mg/kg in Period 1 received a single dose of MRX1 2.5 mg/kg after consuming a high-fat, high-calorie meal.
お知らせ • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.
お知らせ • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".
お知らせ • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom
お知らせ • Jul 19Ananda Pharma Limited Doses First Patient In ACTiON Clinical Trial For MRX1 In Chemotherapy Induced Peripheral NeuropathyAnanda Pharma Limited has dosed the first patient in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's proprietary CBD-based drug candidate, in treatment of patients with Chemotherapy Induced Peripheral Neuropathy. The patient has been recruited, randomised and has taken their first dose of either MRX1 or placebo on the trial. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research as a non-dilutive Efficacy and Mechanism Evaluation grant, is designed to assess the efficacy and safety of MRX1 in the treatment of Chemotherapy Induced Peripheral Neuropathy. It will also assess the impact of MRX1 on quality of life and healthcare utilisation. The trial is a double-blind, placebo-controlled, crossover study with a target enrolment of 92 participants. Chemotherapy Induced Peripheral Neuropathy is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of Chemotherapy Induced Peripheral Neuropathy per year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTiON (Chemotherapy Induced Peripheral Neuropathy, funded by an NIHR Efficacy and Mechanism Evaluation grant).
お知らせ • Jul 06Ananda Pharma Delivers MRX1 Investigational Product To University Of Edinburgh Central Pharmacy For ACTiON Phase 2 Clinical TrialAnanda Pharma announced the MRX1 investigational product manufactured in 2025 has been delivered to the University of Edinburgh central pharmacy. This shipment supports the initiation of the ACTiON Phase 2 clinical trial, which is being run in partnership with the University of Edinburgh. Participant screening is now underway at the clinical trial site in preparation for first participant first dose. This milestone marks a significant step on the clinical development pathway as it brings Ananda closer to dosing its first ever Phase 2 clinical trial patient with MRX1, following the successful completion of its first in-human study earlier this year. The Company will provide further updates when first participant first dose has been confirmed. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR) as an Efficacy and Mechanism Evaluation (EME) grant, is designed to assess the efficacy and safety of MRX1 in the treatment of CIPN. It will also assess the impact of MRX1 on quality of life and health care utilisation. The trial is a double-blind, placebo controlled, crossover study with a target enrolment of 92 participants. CIPN is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of CIPN/year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University of Edinburgh.
お知らせ • Jun 19+ 1 more updateAnanda Pharma Limited Completes Phase 1 MRX1 Pharmacokinetic Study and Confirms Favourable Safety and TolerabilityAnanda Pharma Limited has completed its Phase 1 pharmacokinetic study, yielding highly encouraging data that confirms favourable safety and tolerability and dose selection for future clinical studies. The positive outcomes of the study support continued clinical investigation into Phase 2 and provide further confidence in the Company's clinical and regulatory strategy. MRX1 demonstrated a favourable tolerability profile under the conditions evaluated in healthy volunteers following twice daily dosing for 6 days at dosing levels of 2.5 mg/kg and 7.5 mg/kg per dose under fasted conditions and following a single dose at 2.5 mg/kg under fed conditions. All reported Treatment Emergent Adverse Events ('TEAEs') were mild in severity. There were no moderate or severe TEAEs or TEAEs that led to study drug discontinuation, study withdrawal or death. There were no meaningful changes over time observed for any clinical laboratory parameter, and no abnormal clinically significant laboratory parameters were reported at any time during the study, including liver function parameters. This safety and tolerability profile was consistent with the established clinical profile of approved CBD therapies, a finding that supports the scientific rationale underpinning our FDA 505(b)(2) development pathway. The Phase 1 study was designed to assess the pharmacokinetics, safety and tolerability of multiple doses of MRX1 in healthy adult volunteers. Two dose levels were tested, 2.5 and 7.5 mg/kg of body weight. The effect of food was also assessed for lower dose level (2.5 mg/kg). A total of 20 participants received at least one dose of MRX1, with 10 participants 2.5 mg/kg twice daily and 10 receiving 7.5 mg/kg twice daily. After a 14-day wash-out period, 9 of the 10 participants who had previously been dosed with MRX1 2.5 mg/kg in Period 1 received a single dose of MRX1 2.5 mg/kg after consuming a high-fat, high-calorie meal.
お知らせ • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.
お知らせ • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".
お知らせ • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom
